2 weeks Ago By ABMN Staff
Prudential Financial Inc. lowered its stake in Arrowhead Pharmaceuticals, Inc. ( NASDAQ:ARWR – Free Report ) by 7.
2% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 12,285 shares of the biotechnology company’s stock after selling 949 shares during the period. Prudential Financial Inc.
’s holdings in Arrowhead Pharmaceuticals were worth $228,000 as of its most recent SEC filing. A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. R Squared Ltd bought a new position in Arrowhead Pharmaceuticals during the 4th quarter worth approximately $38,000.
Van ECK Associates Corp boosted its stake in shares of Arrowhead Pharmaceuticals by 72.3% during the fourth quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company’s stock valued at $56,000 after purchasing an additional 1,250 shares during the period.
KBC Group NV grew its holdings in shares of Arrowhead Pharmaceuticals by 45.9% in the fourth quarter. KBC Group NV now owns 5,224 shares of the biotechnology company’s stock worth $98,000 after purchasing an additional 1,644 shares during the last quarter.
Envestnet Portfolio Solutions Inc. bought a new position in shares of Arrowhead Pharmaceuticals in the fourth quarter worth approximately $190,000. Finally, First Citizens Bank & Trust Co.
purchased a new position in shares of Arrowhead Pharmaceuticals in the fourth quarter worth $205,000. Institutional investors own 62.61% of the company’s stock.
Arrowhead Pharmaceuticals Stock Down 5.8 % Shares of NASDAQ:ARWR opened at $11.11 on Friday.
The firm has a market capitalization of $1.53 billion, a P/E ratio of -2.15 and a beta of 0.
99. The company has a debt-to-equity ratio of 7.27, a quick ratio of 6.
09 and a current ratio of 6.09. The stock has a 50 day moving average price of $16.
23 and a 200-day moving average price of $18.91. Arrowhead Pharmaceuticals, Inc.
has a 52-week low of $9.57 and a 52-week high of $30.41.
Insider Buying and Selling In related news, CEO Christopher Richard Anzalone sold 133,333 shares of the company’s stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $17.02, for a total value of $2,269,327.
66. Following the sale, the chief executive officer now owns 3,773,802 shares in the company, valued at $64,230,110.04.
This represents a 3.41 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink .
Insiders sold a total of 185,717 shares of company stock worth $3,064,441 in the last three months. 4.30% of the stock is owned by corporate insiders.
Analyst Ratings Changes ARWR has been the subject of several analyst reports. Chardan Capital reissued a “buy” rating and set a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th.
HC Wainwright reiterated a “buy” rating and set a $80.00 target price on shares of Arrowhead Pharmaceuticals in a report on Wednesday, February 12th. B.
Riley reissued a “buy” rating and issued a $38.00 target price (down from $51.00) on shares of Arrowhead Pharmaceuticals in a research note on Friday, February 14th.
Royal Bank of Canada reaffirmed an “outperform” rating and set a $42.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. Finally, StockNews.
com upgraded Arrowhead Pharmaceuticals to a “sell” rating in a research report on Friday, December 20th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.
com, the company has an average rating of “Hold” and an average target price of $41.44. Get Our Latest Stock Report on ARWR Arrowhead Pharmaceuticals Profile ( Free Report ) Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States.
The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. Featured Stories Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter .
.
